A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes

This CME/NCPD/CPE activity includes five individual interactive, microlearning modules addressing care and outcomes for individuals with diabetes treated with mealtime insulin (MTI).  The modules incorporate case studies with embedded questions for an active learning experience. Learners can choose to participate in one or more of the modules to address their educational interests and needs based on their scope of practice and patient population.

In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative approach is not only necessary for managing patients with B-cell cancers, such as CLL and MCL, but can also improve patient outcomes through monitoring and managing adverse events.

An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies.

After more than a decade of limited progress, the clinical management of advanced biliary tract cancers is rapidly changing. The introduction of new systemic therapies and the increased understanding of clinically actionable mutations in biliary tract cancers have led to the development of several biomarker-guided treatments and other promising strategies. In this activity, an oncology advanced practice provider discusses the latest clinical data regarding recently validated and forthcoming therapeutic strategies for patients with biliary tract cancers and the nurse’s role in improving patient outcomes through patient education, monitoring for and managing treatment-related toxicities, and counseling patients on therapeutic options, including clinical trial enrollment.

In this activity, an expert in pulmonology discusses the latest clinical research and treatment guidelines on approved biologic therapies for the management of adult and pediatric patients with uncontrolled moderate to severe asthma.

In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered.

In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis.

In this activity, an expert in atopic dermatitis discusses practical strategies for selecting treatment for pediatric and adult patients.

Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination strategies likely to affect patient care.

In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.